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AbstrAct:
The ability of a potential human anti-cancer therapeutic agent to inhibit the growth of 
xenografted tumors in nude mice has been an established and accepted testing method 
for several decades. The current report shows that a single, low-level intravenous 
dose of [32P]ATP significantly inhibits the growth of established xenografted tumors 
in nude mice.  This inhibitory effect becomes appreciable very rapidly, within only 
five days post-injection and the low dose demonstrates little or no toxicity in the 
mice. Surprisingly, a narrow dose window of optimum effectiveness is seen, whereby 
either decreasing or increasing the [32P]ATP dose results in far less growth inhibition. 
Thus, the intravenous systemic injection of [32P]ATP may represent a simple, 
potent method to target and inhibit primary human tumors and malignant lesions.
INtrODUctION
Radioisotopes that emit beta particles can 
effectively kill target tumor cells. This therapeutic effect 
is exemplified by the ability of 131I to home naturally to 
thyroid  tissue,  resulting  in  very  efficient  treatment  of 
thyroid cancer and Graves’ Disease. Two FDA-approved 
radioimmunotherapeutics utilizing antibodies against the 
CD20 cell surface marker, 131I-Bexxar and 90Y-Zevalin, 
are currently approved for the treatment of non-
Hodgkin’s lymphoma [1,2]. In addition, neuroendocrine 
tumors can be treated with 90Y-radiolabeled somatostatin. 
The maximum beta energy of electrons emitted by [32P]
ATP, the isotope utilized in the current experiments, lies 
intermediate between that of 90Yttrium and 131Iodine and 
has a path length range of up to 5 mm. in tissues. This 
range means that each electron penetrates hundreds to 
thousands of cells, resulting in a “bystander effect” that 
amplifies the killing power of each 32P atom in or near a 
tumor. The longer half-life of 32P compared to these other 
two isotopes represents an advantage, because the level 
of radioactivity present in the tumor will not diminish as 
rapidly due to natural decay.
For decades, evaluation of potential anticancer 
therapeutics has relied on their capacity to inhibit the 
growth of xenografted tumors in nude mice [3,4]. 
Successful drugs have included antibodies directed 
against cell surface molecules (e.g., Rituxan), or against 
broader targets, such as inhibition of the establishment 
of the tumor microenvironment (by anti-VEGF, e.g., 
Avastin) or the targeting of rapidly growing cells (by 
cisplatin) [5]. In general, smaller anti-cancer therapeutic 
molecules offer better tumor penetration as well as lower 
immunogenicity. The current report establishes that a 
single, low-dose intravenous injection of [32P]ATP rapidly 
and effectively inhibits the growth of xenografted tumors 
in nude mice. These tumors are already vascularized and 
established before the dose is administered, and a narrow 
dose window of effectiveness is seen. 
rEsULts
Inhibition of xenografted tumor growth
Ten week old nude mice received subcutaneous 
injections of human colon adenocarcinoma cell line Oncotarget 2011; 2:  461 - 466 462 www.impactjournals.com/oncotarget
HCT116  in  the  left  rear  flank  and  human  cervical 
carcinoma cell line HeLa in the right rear flank. By Day 9 
the xenografted tumors were established and vascularized, 
at which time groups of five to six mice received a single 
intravenous tail vein injection of 1, 5, 10 or 25 µCi of 
[32P]ATP. Figure 1 shows the measured tumor volumes of 
the HeLa-derived xenografted tumors beginning at Day 
11, two days after the radioactive dose was administered. 
Within one week of the [32P]ATP injection (by Day 16), a 
strong inhibition of xenografted tumor growth occurred 
at the 5 µCi dose level. This inhibition of tumor growth 
strengthened over the next two weeks, and a narrow 
optimal dose window was observed, which centered at 
5 µCi. None of the mice used in any experiment in this 
report ever demonstrated any sign of radiation toxicity 
(i.e., weight loss or by any diminution of mobility or 
activity). 
In our experiments, HCT116-derived tumors grew 
approximately  five  times  faster  than  did  Hela-derived 
tumors. Figure 2A shows that the 5 µCi [32P]ATP dose 
was significantly superior to the 10 µCi dose in inhibiting 
tumor growth from HCT116-derived tumors, although 
this inhibition required one extra week versus the first 
appearance of inhibition in HeLa-derived tumors. Figure 
2B reveals that the average volume of the HeLa-derived 
tumors in the mice receiving the 5 µCi soon plateaued, 
and then began to decrease by ten days [32P]ATP post-
injection (at Day 19). Surprisingly, mice that received 
only a twice-greater dose (10 µCi) demonstrated greatly 
decreased tumor growth inhibition, and the tumor volume 
difference between mice receiving the 5 µCi versus the 10 
µCi dose became extremely significant over the ensuing 
two weeks (P<0.004).
Confirmation of growth inhibition using a second 
HeLa cell isolate
 The HeLa cell isolate used to establish the tumors 
shown in Figures 1 and 2 had been grown continuously in 
cell culture for more than four years. Cell lines grown in 
cell culture for extended periods can alter their genotypes 
and phenotypic attributes. Therefore, to test and establish 
the most reproducible system possible, a different isolate 
of HeLa was purchased from ATCC, grown in cell culture 
for two weeks, and used immediately to establish the 
Figure 1: Inhibition of xenografted tumor growth. HeLa cells (right rear flank) were used to establish xenografted tumors and 
were injected subcutaneously on Day 1. One of four different amounts of [32P]ATP was injected intravenously on Day 9. Means of the 
daily tumor volume measurement from Day 11 through Day 30 demonstrated a strong but narrow dose window of tumor growth inhibition 
centered at 5 µCi. Tumor volumes are 1000 x mm3.
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HeLa-derived tumors in Figures 3 and 4. Figure 3 shows 
daily tumor volumes measured from multiple groups 
of nude mice that had been injected with HeLa cells 
subcutaneously on both the left rear and right rear flanks 
on Day 1, followed by one of seven different doses of 
intravenous [32P]ATP injected intravenously on Day 9. A 
narrow, but clearly defined dose window is evident, with 
maximum tumor growth inhibition occurring at 7.5 µCi. 
Significantly less inhibition was seen with [32P]ATP doses 
only 2.5 µCi above and below this optimal level. Figures 
4A and 4B reveal the speed and magnitude at which these 
growth rate differences emerge in 7.5 µCi versus 50 µCi 
or 1 µCi doses, respectively. 
DIscUssION
  The  mechanism  for  the  reproducible  finding  of 
low-dose [32P]ATP-induced tumor growth inhibition 
is not understood at this time. We speculate that this 
effect may be due to a combination of factors, such as 
the direct cell-killing ability of the radioisotope, injury 
to the B cells and natural killer cells that are present and 
active in nude mice, and the phenomenon of low-dose 
radiation hypersensitivity of certain cells [6]. Inorganic 
elemental 32P has been used clinically to treat very high 
levels of platelets or red blood cells, thrombocythemia 
and polycythemia vera, respectively, and up to 15 mCi 
of inorganic sodium phosphate 32P can be administered to 
patients with chronic leukemia [7]. However, organic 32P, 
specifically in the form of [32P]ATP, has to our knowledge, 
not been reported in a therapeutic context. The levels of 
[32P]ATP used in nude mice in this report, correspond on 
a weight basis, to comparable levels of inorganic 32P used 
in accepted human treatments. In addition, current clinical 
trials utilize inorganic forms of 32P and nanotechnology 
techniques to attempt to deliver the radioisotope to target 
cells and cancers.
Previous studies found extracellular ATP at 
Figure 2: The human colon cancer cell line HCT116 (left rear flank) or HeLa cells (right rear flank) were used to 
establish xenografted tumors and were injected subcutaneously on Day 1. One of four different amounts of [32P]ATP was 
injected intravenously on Day 9. Significant tumor growth inhibition by comparing 5 µCi versus 10 µCi doses against HCT116-derived 
xenografted tumors (A) or by 5 µCi versus 10 µCi doses against Hela-derived tumors (B) was detected as soon as Day 16, seven days after 
the [32P]ATP injections. The means and plus/minus one standard deviation are shown and the bold numbers are P values determined by the 
two-sided student’s t test. Tumor volumes are 1000 x mm3.
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concentrations in excess of 100 µM in xenografted 
mouse tumors, but undetectable levels in healthy tissues 
[8]. Exogenously administered [32P]ATP may constitute 
a naturally targeted anticancer therapeutic agent and 
may involve cancer-related inflammation and the tumor 
microenvironment [9]. Additional advantages of the 
[32P]ATP molecule include the facts that 1) it is readily 
accessible and inexpensive, 2) it is a pure beta particle 
emitter with an average beta energy greater than 131I, 3) 
it is easy to handle, and 4) it has a long half-life greater 
than two weeks. In addition to producing humanized 
antibodies that diminish the patient’s immune response 
against the Ab-based anti-cancer agent, bioengineering 
has also yielded smaller antibody molecules to enhance 
tumor penetration. Classically, anti-cancer molecules of 
smaller sizes often demonstrate better tumor penetration 
[10]. With a molecular weight of approximately 508 
Daltons, [32P]ATP is extremely small relative to almost 
any other proposed or active anti-cancer agents, with the 
exception of 131I. [32P]ATP appears to take advantage of 
a natural tumor-homing ability and a unique requirement 
for exogenous ATP by the tumor microenvironment for 
its establishment and growth. Finally, the intravenous 
systemic injection of [32P]ATP may represent a simple, yet 
potent method to target and inhibit primary human tumors 
and malignant lesions. 
MAtErIAL AND MEtHODs
Cell lines used to establish nude mouse xenografted 
tumors
All cell lines were purchased from ATCC and 
grown in MEM with 10% fetal bovine serum and Pen/
Strep antibiotics. The HCT116 cell line used to establish 
the xenografted tumors shown in Figure 2A was grown in 
cell culture for approximately six months before injection, 
and the HeLa cell line shown in Figure 1 and in Figure 
2B was grown in cell culture for approximately four years 
before injection. In an effort to maximize reproducibility 
Figure 3: Inhibition of xenografted tumor growth. Nude mice were injected subcutaneously with Hela cells to establish xenografted 
tumors on Day 1 and one of seven different amounts of [32P]ATP was injected intravenously on Day 9 (arrow). Means of the daily tumor 
volume measurement from Day 8 through Day 26 demonstrated a narrow dose window of tumor growth inhibition centered at 7.5 µCi. 
Tumor volumes are 1000 x mm3.
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in all experiments, the HeLa cell line used to establish 
the xenografted tumors in Figure 3 and in Figure 4 was 
purchased from ATCC, grown in cell culture for two 
weeks and then injected subcutaneously. The identities of 
all cell lines were confirmed using a short tandem repeat 
assay (Promega PowerPlex). The two HeLa cell lines were 
confirmed to be HeLa cells, although they were different 
isolate clones obtained from ATCC, as was expected.
Establishment  of  xenografted  tumors  and 
injection of radioisotope in athymic nude mice
2 X 106 cells in Matrigel (50%)/ 1 X PBS (50%) 
in 0.2 ml were injected subcutaneously into the left rear 
or right rear flank of female nude mice (Charles River, 
Boston) that were nine to ten weeks of age. [32P]ATP 
(3000 Ci/mmol) was purchased from Perkin Elmer and 
the indicated dose was injected in 0.1 ml of 1 X HBSS 
via the tail vein. Mouse weight and tumor volume were 
measured daily. The width (W) and length (L) of the 
tumor were measured using a digital caliper and the 
volume determined using the formula V = ½(L X W2). 
Five or six mice were used in each group. No mice in any 
experiments shown in Figures 1, 2, 3, or 4 showed any 
signs of toxicity as determined by significant differences 
in weight or by general activity levels. The xenografted 
tumor growth patterns seen at the 7.5 µCi [32P]ATP dose 
in Figures 3 and 4 and at the 5 µCi [32P]ATP dose seen 
Figure 4: Nude mice were injected subcutaneously with Hela cells to establish xenografted tumors on Day 1 and one 
of different amounts of [32P]ATP was injected intravenously on Day 9. Significant tumor growth inhibition by 7.5 µCi versus 
50 µCi (A) or by 7.5 µCi versus 1 µCi (B) was detected as soon as Day 14, five days after the [32P]ATP injections. The means and plus/
minus one standard deviation are shown and the bold numbers are P values determined by the two-sided student’s t test. Tumor volumes 
are 1000 x mm3.
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in Figures 1 and 2 have xenografted tumors established 
and vascularized, with a steady tumor volume increase 
until the [32P]ATP is injected. At the optimal dose, after 
a few days, the growth patterns plateau and the tumor 
volume slightly declines, beginning as soon as five days 
post-injection. Approximately two weeks after [32P]ATP 
injection, a slight increase in tumor volume is observed at 
the optimal dose levels.
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